SEATTLE--(BUSINESS WIRE)--Amkor Pharmaceuticals, Inc. today provides a progress report on its phase 1 clinical study of Neu2000KL. Neu2000KL is a multi-mechanism neuroprotectant that is being developed for the treatment of ischemic stroke and sudden cardiac arrest. The drug is both a potent anti-oxidant and an NMDA antagonist. These therapeutic mechanisms have been among the most sought after activities in the pharmaceutical development of neuroprotectants over the past few decades, and Neu2000KL is believed to be the first drug candidate to combine both of these important activities into a single drug agent. The drug has been shown to be effective in numerous animal models of ischemic stroke and sudden cardiac arrest.
